Tolosa, P., Garcia Fructuoso, I., Pascual, T., Martínez-Sáez, O., Cejalvo Andújar, J. M., Servitja, S., . . . Ciruelos, E. (2026). Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: The SOLTI-1801 CDK-PREDICT study.
Citación estilo ChicagoTolosa, Pablo, et al. Real-world Second- and Third-line Progression-free Survival After Progression On First-line CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer By PAM50 Intrinsic Subtype: The SOLTI-1801 CDK-PREDICT Study. 2026.
Cita MLATolosa, Pablo, et al. Real-world Second- and Third-line Progression-free Survival After Progression On First-line CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer By PAM50 Intrinsic Subtype: The SOLTI-1801 CDK-PREDICT Study. 2026.